Cover
Cover - shares | 3 Months Ended | |
Mar. 31, 2022 | May 13, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Mar. 31, 2022 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2022 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 000-54748 | |
Entity Registrant Name | ETHEMA HEALTH CORPORATION. | |
Entity Central Index Key | 0000792935 | |
Entity Tax Identification Number | 84-1227328 | |
Entity Incorporation, State or Country Code | CO | |
Entity Address, Address Line One | 1590 S. Congress Avenue | |
Entity Address, City or Town | West Palm Beach | |
Entity Address, State or Province | FL | |
Entity Address, Postal Zip Code | 33406 | |
City Area Code | 561 | |
Local Phone Number | 290-0239 | |
Title of 12(b) Security | Common shares | |
Trading Symbol | GRST | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 3,729,053,805 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Current assets | ||
Cash | $ 27,024 | $ 48,822 |
Accounts receivable, net | 291,011 | 176,011 |
Prepaid expenses | 19,277 | 29,731 |
Other current assets | 18,406 | 17,235 |
Total current assets | 355,718 | 271,799 |
Non-current assets | ||
Due on sale of subsidiary | 5,190 | 5,115 |
Property and equipment | 3,082,878 | 3,012,663 |
Intangible assets, net | 1,521,418 | 1,610,913 |
Right of use assets | 1,590,752 | 1,653,816 |
Total non-current assets | 6,200,238 | 6,282,507 |
Total assets | 6,555,956 | 6,554,306 |
Current liabilities | ||
Accounts payable and accrued liabilities | 360,310 | 438,482 |
Taxes payable | 717,665 | 658,836 |
Convertible loans, net of discounts | 4,831,880 | 4,891,938 |
Short term loans | 249,522 | 122,167 |
Mortgage loans | 3,890,306 | 3,864,312 |
Government assistance loans | 157,367 | 157,367 |
Operating lease liability | 252,340 | 241,083 |
Finance lease liability | 7,507 | 7,386 |
Derivative liability | 278,699 | 515,901 |
Accrued dividends | 131,072 | 105,049 |
Related party payables | 2,792,941 | 2,514,281 |
Total current liabilities | 13,669,609 | 13,516,802 |
Non-current liabilities | ||
Government assistance loans | 48,015 | 47,326 |
Deferred taxation | 254,263 | 273,057 |
Third party loans | 588,562 | 646,176 |
Operating lease liability | 1,425,018 | 1,493,431 |
Finance lease liability | 30,951 | 32,895 |
Total non-current liabilities | 2,346,809 | 2,492,885 |
Total liabilities | 16,016,418 | 16,009,687 |
Preferred stock - Series B; $1.00 par value, 10,000,000 authorized, 400,000 shares outstanding at March 31, 2022 and December 31, 2021. | 400,000 | 400,000 |
Stockholders’ deficit | ||
Preferred stock - Series A; $0.01 par value, 10,000,000 authorized, 4,000,000 shares outstanding at March 31, 2022 and December 31, 2021. | 40,000 | 40,000 |
Common stock - $0.01 par value, 10,000,000,000 shares authorized; 3,729,053,805 and 3,579,053,805 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively. | 37,290,539 | 35,790,539 |
Additional paid-in capital | 22,791,350 | 22,791,350 |
Discount for shares issued below par value | (27,363,367) | (26,013,367) |
Accumulated other comprehensive income | 851,049 | 816,532 |
Accumulated deficit | (44,302,371) | (44,103,311) |
Stockholders’ deficit attributable to Ethema Health Corporation stockholders | (10,692,800) | (10,678,257) |
Non-controlling interest | 832,338 | 822,876 |
Total stockholders’ deficit | (9,860,462) | (9,855,381) |
Total liabilities and stockholders’ deficit | $ 6,555,956 | $ 6,554,306 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares | Mar. 31, 2022 | Dec. 31, 2021 |
Common Stock, Par or Stated Value Per Share | $ 0.01 | $ 0.01 |
Common Stock, Shares Authorized | 10,000,000,000 | 10,000,000,000 |
Common Stock, Shares issued | 3,729,053,805 | 3,579,053,805 |
Common Stock, Shares, Outstanding | 3,729,053,805 | 3,579,053,805 |
Series B Preferred Stock [Member] | ||
Preferred Stock, Par or Stated Value Per Share | $ 1 | $ 1 |
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 |
Preferred Stock, Shares Outstanding | 400,000 | 400,000 |
Series A Preferred Stock [Member] | ||
Preferred Stock, Par or Stated Value Per Share | $ 0.01 | $ 0.01 |
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 |
Preferred Stock, Shares Outstanding | 4,000,000 | 4,000,000 |
UNAUDITED CONDENSED CONSOLIDATE
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Income Statement [Abstract] | ||
Revenues | $ 1,023,315 | $ 90,793 |
Operating expenses | ||
General and administrative | 209,932 | 5,503 |
Rent expense | 90,031 | 1,500 |
Management fees | 30,000 | |
Professional fees | 49,587 | 36 |
Salaries and wages | 436,825 | 12,852 |
Depreciation expense | 132,000 | 32,125 |
Total operating expenses | 948,375 | 52,016 |
Operating Income | 74,940 | 38,777 |
Other (expense) income | ||
Other income | 10,018 | |
Warrants exercised | (90,000) | |
Fair value of warrants granted to convertible note holders | (976,788) | |
Penalty on convertible notes | (9,240) | |
Interest expense | (80,768) | (137,677) |
Amortization of debt discount | (252,832) | (502,677) |
Derivative liability movement | 197,476 | (611,059) |
Foreign exchange movements | (95,556) | (79,492) |
Net loss before taxation | (146,722) | (2,368,156) |
Taxation | (18,263) | |
Net loss | (164,985) | (2,368,156) |
Net income attributable to non-controlling interest | (9,462) | |
Net loss attributable to Ethema Health Corporation Stockholders’ | (174,447) | (2,368,156) |
Preferred stock dividend | (24,613) | (30,847) |
Net loss available to common shareholders of Ethema Health Corporation | (199,060) | (2,399,003) |
Foreign currency translation adjustment | 34,517 | 29,606 |
Total comprehensive loss | $ (164,543) | $ (2,369,397) |
Basic and diluted loss per common share | $ 0 | $ 0 |
Weighted average common shares outstanding – Basic and diluted | 3,630,720,472 | 2,143,692,378 |
UNAUDITED CONDENSED CONSOLIDA_2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($) | Series A Preferred Stocks [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Discount To Par Value [Member] | Comprehensive Income [Member] | Retained Earnings [Member] | Noncontrolling Interest [Member] | Total |
Beginning balance, value at Dec. 31, 2020 | $ 40,000 | $ 20,270,857 | $ 23,344,885 | $ (17,728,779) | $ 806,719 | $ (42,459,781) | $ 700,000 | $ (15,026,099) |
Beginning Balance, Shares at Dec. 31, 2020 | 4,000,000 | 2,027,085,665 | ||||||
Fair value of warrants issued to convertible debt holders | 1,207,214 | 1,207,214 | ||||||
Warrants exercised | $ 600,000 | (510,000) | 90,000 | |||||
Warrants exercised, Shares | 59,999,999 | |||||||
Conversion of convertible notes | $ 1,757,635 | 97,000 | (582,850) | 1,271,785 | ||||
Conversion of convertible notes, Shares | 175,763,466 | |||||||
Foreign currency translation | 29,606 | 29,606 | ||||||
Net loss | (2,368,156) | (2,368,156) | ||||||
Dividends accrued | (30,847) | (30,847) | ||||||
Ending balance, value at Mar. 31, 2021 | $ 40,000 | $ 22,628,492 | 24,649,099 | (18,821,629) | 836,325 | (44,858,784) | 700,000 | (14,826,497) |
Ending Balance, Shares at Mar. 31, 2021 | 4,000,000 | 2,262,849,130 | ||||||
Beginning balance, value at Dec. 31, 2021 | $ 40,000 | $ 35,790,539 | 22,791,350 | (26,013,367) | 816,532 | (44,103,311) | 822,876 | (9,855,381) |
Beginning Balance, Shares at Dec. 31, 2021 | 4,000,000 | 3,579,053,805 | ||||||
Conversion of convertible notes | $ 1,500,000 | (1,350,000) | 150,000 | |||||
Conversion of convertible notes, Shares | 150,000,000 | |||||||
Foreign currency translation | 34,517 | 34,517 | ||||||
Net loss | (174,447) | 9,462 | (164,985) | |||||
Dividends accrued | (24,613) | (24,613) | ||||||
Ending balance, value at Mar. 31, 2022 | $ 40,000 | $ 37,290,539 | $ 22,791,350 | $ (27,363,367) | $ 851,049 | $ (44,302,371) | $ 832,338 | $ (9,860,462) |
Ending Balance, Shares at Mar. 31, 2022 | 4,000,000 | 3,729,053,805 |
UNAUDITED CONDENSED CONSOLIDA_3
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Operating activities | ||
Net loss | $ (164,985) | $ (2,368,156) |
Adjustment to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization expense | 132,000 | 32,125 |
Fair value of warrants granted | 976,788 | |
Amortization of debt discount | 252,832 | 502,677 |
Derivative liability movements | (197,476) | 611,059 |
Exercise of warrants | 90,000 | |
Amortization of right of use asset | 63,064 | |
Deferred taxation movement | (18,794) | |
Changes in operating assets and liabilities | ||
Accounts receivable | (115,000) | |
Prepaid expenses | 10,456 | 14,638 |
Other current assets | (1,171) | |
Accounts payable and accrued liabilities | (22,013) | 50,330 |
Operating lease liabilities | (57,156) | |
Taxes payable | 49,169 | 12,983 |
Net cash used in operating activities | (69,074) | (77,556) |
Investing activities | ||
Other investments | (336,220) | |
Purchase of property and equipment | (72,858) | |
Net cash used in investing activities | (72,858) | (336,220) |
Financing activities | ||
Repayment of mortgage | (29,850) | (28,631) |
Proceeds from convertible notes | 340,000 | |
Repayment of convertible notes | (201,733) | (35,000) |
Proceeds from promissory notes | 100,000 | |
Proceeds from government assistance loans | 15,797 | |
Repayment of third party loans | (78,977) | |
Repayment of finance leases | (1,822) | |
Proceeds from related party notes | 259,228 | |
Repayment of related party notes | (12,985) | |
Net cash provided by financing activities | 46,846 | 279,181 |
Effect of exchange rate on cash | 73,288 | 79,325 |
Net change in cash | (21,798) | (55,270) |
Beginning cash balance | 48,822 | 90,500 |
Ending cash balance | 27,024 | 35,230 |
Supplemental cash flow information | ||
Cash paid for interest | 43,304 | 41,344 |
Cash paid for income taxes | ||
Non-cash investing and financing activities | ||
Fair value of warrant issued | 230,426 | |
Conversion of convertible notes | $ 150,000 | $ 165,137 |
Nature of business
Nature of business | 3 Months Ended |
Mar. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of business | 1. Nature of business Since 2010, the Company has operated addiction treatment centers. Initially the Company operated an addiction treatment center in Ontario Canada under its Greenestone Muskoka clinic, which was sold on February 14, 2017. Simultaneously with this sale the Company purchased buildings and operated an addiction treatment center in Delray Beach Florida under its Addiction recovery Institute of America subsidiary with a license obtained in December 2016, initially though owned properties in Delray Beach and subsequently though leased properties in West Palm Beach, Florida. Since June 30, 2020, the Company has been actively involved in the management of a treatment center operated by Evernia in West Palm Beach Florida. On July 1, 2021, the Company closed on the acquisition of 75% of ATHI, which owns 100% of Evernia, once the probationary approval of a license was obtained from the Department of Children and Family Services of Florida. Evernia is the only active treatment center operated by the Company. The Company also owns the real estate on which its Greenstone Muskoka clinic operated. The current tenant operates an addiction treatment center on these premises. The Company collects rent on this property, which is treated as a separate business segment. |
Summary of significant accounti
Summary of significant accounting policies | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Summary of significant accounting policies | 2. Summary of significant accounting policies Financial Reporting The (a) unaudited condensed consolidated balance sheets as of March 31, 2022, which have been derived from the unaudited condensed consolidated financial statements, and as of December 31, 2021, which have been derived from audited consolidated financial statements, and (b) the unaudited condensed consolidated statements of operations, stockholders’ deficit and cash flows of the Company, have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of results that may be expected for the year ending December 31, 2022. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on April 14, 2022. All amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise. a) Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. These estimates and assumptions include valuing equity securities issued in share-based payment arrangements, determining the fair value of assets acquired, allocation of purchase price, impairment of long-lived assets, the collectability of receivables, leasing arrangements, convertible debentures, contingencies and the value of deferred taxes and related valuation allowances. Certain estimates, including evaluating the collectability of receivables and advances, could be affected by external conditions, including those unique to the Company’s industry and general economic conditions. It is possible that these external factors could have an effect on the Company’s estimates that could cause actual results to differ from the Company’s estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and record adjustments when necessary. b) Principals of consolidation and foreign currency translation The accompanying condensed consolidated financial statements include the accounts of the Company and all of its subsidiaries. ATHI and its wholly owned subsidiary Evernia, have been consolidated since July 1, 2021. All intercompany transactions and balances have been eliminated on consolidation. Certain of the Company’s subsidiaries functional currency is the Canadian dollar, while the Company’s reporting currency is the U.S. dollar. All transactions initiated in Canadian dollars are translated into US dollars in accordance with ASC 830, “Foreign Currency Translation” as follows: ● Monetary assets and liabilities at the rate of exchange in effect at the balance sheet date. ● Non-monetary, non-current and equity at historical rates. ● Revenue and expense items and cash flows at the average rate of exchange prevailing during the period. Adjustments arising from such translations are deferred until realization and are included as a separate component of stockholders’ deficit as a component of accumulated other comprehensive income or loss. Therefore, translation adjustments are not included in determining net income (loss) but reported as other comprehensive income (loss). For foreign currency transactions, the Company translates these amounts to the Company’s functional currency at the exchange rate effective on the invoice date. If the exchange rate changes between the time of purchase and the time actual payment is made, a foreign exchange transaction gain or loss results which is included in determining net income for the period. The relevant translation rates are as follows: For the three months ended March 31, 2022, a closing rate of CDN$1.0000 equals US$0.8003 and an average exchange rate of CDN$1.0000 equals US$0.78980. For the three months ended March 31, 2021, a closing rate of CAD$1.0000 equals US$0.7952 and an average exchange rate of CAD$1.0000 equals US$0.7899. c) Business Combinations The Company allocates the fair value of purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired users, acquired technology, and trade names from a market participant perspective, useful lives and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. d) Cash and cash equivalents For purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with several financial institutions in the USA and Canada. The Company primarily places cash balances in the USA with high-credit quality financial institutions located in the United States which are insured by the Federal Deposit Insurance Corporation up to a limit of $250,000 per institution, in Canada which are insured by the Canadian Deposit Insurance Corporation up to a limit of CDN$100,000 per institution. e) Accounts receivable Accounts receivable primarily consists of amounts due from third-party payors (non-governmental) and private pay patients and is recorded net of allowances for doubtful accounts and contractual discounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s consolidated financial statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimating net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies denying claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients. f) Allowance for Doubtful Accounts, Contractual and Other Discounts The Company derives the majority of its revenues from commercial payors at in-network rates. Management estimates the allowance for contractual and other discounts based on its historical collection experience. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account is written off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made. g) Property and equipment Property and equipment is recorded at cost. Depreciation is calculated on the straight line basis over the estimated life of the asset. h) Intangible assets Intangible assets are stated at acquisition cost less accumulated amortization, if applicable, less any adjustments for impairment losses. Amortization is charged on a straight-line basis over the estimated remaining useful lives of the individual intangibles. Where intangibles are deemed to be impaired the Company recognizes an impairment loss measured as the difference between the estimated fair value of the intangible and its book value. Licenses to provide substance abuse rehabilitation services are amortized over the expected life of the contract, including any anticipated renewals. The Company expects its licenses to remain in operation for a period of five years. i) Leases The Company accounts for leases in terms of AC 842 whereby leases are classified as either capital or operating leases. Leases that transfer substantially all of the benefits and inherent risks of ownership of property to the Company are accounted for as capital leases. At the time a capital lease is entered into, an asset is recorded together with its related long-term obligation to reflect the acquisition and financing. Equipment recorded under capital leases is amortized on the same basis as described above. Operating leases are recognized on the balance sheet as a lease liability with a corresponding right of use asset for all leases with a term that is more than twelve months. Payments under operating leases are expensed as incurred. j) Derivatives The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. The Company uses a Black Scholes Option Pricing model to estimate the fair value of convertible debt conversion features at the end of each applicable reporting period. Changes in the fair value of these derivatives during each reporting period are included in the statements of operations. Inputs into the Black Scholes Option Pricing model require estimates, including such items as estimated volatility of the Company’s stock, risk free interest rate and the estimated life of the financial instruments being fair valued. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion feature. k) Financial instruments The Company initially measures its financial assets and liabilities at fair value, except for certain non-arm’s length transactions. The Company subsequently measures all its financial assets and financial liabilities at amortized cost. Financial assets measured at amortized cost include cash and accounts receivable. Financial liabilities measured at amortized cost include bank indebtedness, accounts payable and accrued liabilities, harmonized sales tax payable, withholding taxes payable, convertible notes payable, loans payable and related party notes. Financial assets measured at cost are tested for impairment when there are indicators of impairment. The amount of the write-down is recognized in net income. The previously recognized impairment loss may be reversed to the extent of the improvement, directly or by adjusting the allowance account, provided it is no greater than the amount that would have been reported at the date of the reversal had the impairment not been recognized previously. The amount of the reversal is recognized in net income. The Company recognizes its transaction costs in net income in the period incurred. However, financial instruments that will not be subsequently measured at fair value are adjusted by the transaction costs that are directly attributable to their origination, issuance or assumption. FASB ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: ● Level 1. Observable inputs such as quoted prices in active markets; ● Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and ● Level 3. Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions. The Company measures its convertible debt and derivative liabilities associated therewith at fair value. These liabilities are revalued periodically and the resultant gain or loss is realized through the Statement of Operations and Comprehensive Loss. l) Related parties Parties are considered to be related to the Company if the parties directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged. m) Revenue Recognition ASC 606 requires companies to exercise more judgment and recognize revenue using a five-step process. The Company’s provision for doubtful accounts are recorded as a direct reduction to revenue instead of being presented as a separate line item on the consolidated statements of operations and comprehensive loss. As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities. The Company receives payments from the following sources for services rendered in our U.S. Facility: (i) commercial insurers; and (ii) individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and does not adjust for the effects of a significant financing component. The Company derives a significant portion of its revenue from other payors that receive discounts from established billing rates. The various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management. Settlements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s receivables were $ 291,011 176,011 The Company’s revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those services. The Company derives its revenues from the sale of its services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its revenue transactions: i. identify the contract with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to performance obligations in the contract; and v. recognize revenue as the performance obligation is satisfied. n) Income taxes The Company accounts for income taxes under the provisions of ASC Topic 740, ”Income Taxes”. ASC Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions taken or expected to be taken in a tax return. The first step is to determine if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company recognizes interest and penalties accrued on unrecognized tax benefits within general and administrative expense. To the extent that accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction in general and administrative expenses in the period that such determination is made. o) Net income (loss) per Share Basic net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the period. Diluted net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation. Dilution is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share). p) Stock based compensation Stock based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over the employee’s requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized in the consolidated statements of operations is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. q) Financial instruments Risks The Company is exposed to various risks through its financial instruments. The following analysis provides a measure of the Company’s risk exposure and concentrations at March 31, 2022 and December 31, 2021. i. Credit risk Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Financial instruments that subject the Company to credit risk consist primarily of accounts receivable. Credit risk associated with accounts receivable is mitigated as only a percentage of the revenue billed to health insurance companies is recognized as income until such time as the actual funds are collected. The revenue is concentrated amongst several health insurance companies located in the US. In the opinion of management, credit risk with respect to accounts receivable is assessed as low. ii. Liquidity risk Liquidity risk is the risk the Company will not be able to meet its financial obligations as they fall due. The Company is exposed to liquidity risk through its working capital deficiency of $ 13,313,891 278,699 44,302,371 iii. Market risk Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of three types of risk: interest rate risk, currency risk, and other price risk. The Company is exposed to interest rate risk and currency risk. a. Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its convertible debt, mortgage loans, short term loans, third party loans and government assistance loans as of March 31, 2022. In the opinion of management, interest rate risk is assessed as moderate. b. Currency risk Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company is subject to currency risk as it has subsidiaries that operate in Canada and are subject to fluctuations in the Canadian dollar. A substantial portion of the Company’s financial assets and liabilities are denominated in Canadian dollars. Based on the net exposures at March 31, 2022, a 5% depreciation or appreciation of the Canadian dollar against the U.S. dollar would result in an approximate $4,164 increase or decrease in the Company’s after tax net income from operations. The Company has not entered into any hedging agreements to mitigate this risk. In the opinion of management, currency risk is assessed as low, material and remains unchanged from that of the prior year. c. Other price risk Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. In the opinion of management, the Company is not exposed to this risk and remains unchanged from the prior year. r) Recent accounting pronouncements In August 2020, the Financial Accounting Standard board (“FASB”) issued ASU 2020-06 "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40) ("ASU 2020-06"). The update simplifies the accounting for convertible debt instruments and convertible preferred stock by reducing the number of accounting models and limiting the number of embedded conversion features separately recognized from the primary contract. The guidance also includes targeted improvements to the disclosures for convertible instruments and earnings per share. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company is assessing the impact, if any, on the adoption of this update on the Company's consolidated financial statements. The FASB issued several additional updates during the period, none of these standards are either applicable to the Company or require adoption at a future date and none are expected to have a material impact on the consolidated financial statements upon adoption. t) Comparative and prior period disclosures The comparative and prior period disclosed amounts presented in these unaudited condensed consolidated financial statements have been reclassified where necessary to conform to the presentation used in the current period. |
Going concern
Going concern | 3 Months Ended |
Mar. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Going concern | 3. Going concern The Company’s condensed consolidated financial statements have been prepared in accordance with US GAAP applicable to a going concern, which assumes that the Company will be able to meet its obligations and continue its operations in the normal course of business. At March 31, 2022 the Company has a working capital deficiency of $13.3 million, including derivative liabilities of $0.3 million and total liabilities in excess of assets in the amount of $9.5 million. Management believes that current available resources will not be sufficient to fund the Company’s planned expenditures over the next 12 months. Accordingly, the Company will be dependent upon the raising of additional capital through placement of common shares, and/or debt financing in order to implement its business plan and generating sufficient revenue in excess of costs. If the Company raises additional capital through the issuance of equity securities or securities convertible into equity, stockholders will experience dilution, and such securities may have rights, preferences or privileges senior to those of the holders of common stock or convertible senior notes. If the Company raises additional funds by issuing debt, the Company may be subject to limitations on its operations, through debt covenants or other restrictions. If the Company obtains additional funds through arrangements with collaborators or strategic partners, the Company may be required to relinquish its rights to certain geographical areas, or techniques that it might otherwise seek to retain. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect on the Company’s financial condition. These condensed consolidated financial statements do not include any adjustments to the amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. |
Acquisition of subsidiaries
Acquisition of subsidiaries | 3 Months Ended |
Mar. 31, 2022 | |
Acquisition Of Subsidiaries | |
Acquisition of subsidiaries | 4. Acquisition of subsidiaries On June 30, 2020, the Company entered into an agreement whereby the Company agreed to acquire 51% of American Treatment Holdings, Inc. (“ATHI”) from The Q Global Trust (“Seller”) and Lawrence B Hawkins (“Hawkins”), which in turn owns 100% of Evernia Health Services LLC. (“Evernia”), which operates drug rehabilitation facilities. The consideration for the acquisition was a loan to be provided by the purchaser to Evernia in the amount of $500,000. As of the date of acquisition, July 1, 2021, the Company had advanced Evernia approximately $1,140,985. The Company originally had a 180 day option, from the advancement of the first tranche to Evernia, to purchase an additional 9% of ETHI for a purchase consideration of $50,000. On April 28, 2021, the Stock Purchase Agreement date June 30, 2020 between the Company and the Q Global Trust, and ATHI was amended whereby the option to purchase an additional 9% of ATHI for $50,000 was amended to purchase an additional 24%, an increase of 15% over the prior option, for 100,000,000 shares of common stock. The remaining condition to closing, the receipt of approval for the change of ownership of the license from the Department of Children and Family Services of Florida, was satisfied by the probationary approval, which was received on June 30, 2021. The Company exercised the option and issued the 100,000,000 shares of common stock and paid $42,500 of the $50,000 due to the Seller, in terms of the amended agreement as of the date of this report. In addition to the consideration paid for the additional equity the Company agreed to execute a promissory note for the payment of any unpaid management fees at the time of Closing such that the unpaid fees shall be paid pari-passu with the repayment of the Loan Agreement and Seller agrees that any funds advanced to the Company by Behavioural Health Holdings, LLC shall be forgiven and considered contributed capital to ATHI. The Company agrees to advance up to $1,100,000 under the Loan Agreement for the funding of the operations of ATHI as required without any contribution required by the Seller. Pursuant to the terms of the Purchase Agreement, the consideration paid for 75% of the equity of ATHI was $50,000 in cash plus the issuance of 100,000,000 shares of the Company’s common stock with a market value of $410,000 on the date of acquisition. In terms of the agreement, the preliminary purchase price was allocated to the fair market value of tangible and intangible assets acquired and liabilities assumed as follows: Schedule of assets acquired and liabilities assumed Amount Consideration Cash 50,000 100,000,000 shares of common stock at fair market value 410,000 Total purchase consideration $ 460,000 Recognized amounts of identifiable assets acquired and liabilities assumed Cash 60,324 Other Current assets 198,133 Property, plant and equipment 130,234 Right of use asset 1,772,560 Intangibles 1,789,903 Total assets 3,951,154 Less: liabilities assumed Current liabilities assumed (50,040 ) Intercompany advance (1,140,985 ) Operating lease liabilities assumed (1,836,151 ) Imputed Deferred taxation on identifiable intangible acquired (310,645 ) Total liabilities (3,337,821 ) Net identifiable assets acquired and liabilities assumed 613,333 Fair value of non-controlling interest (153,333 ) Total $ 460,000 The amount of revenue and earnings include in the Company’s condensed consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2022 and the revenue and earnings of the combined entity had the acquisition date been January 1, 2021. Schedule of revenue and earnings Revenue Earnings Actual from January 1, 2022 to March 31, 2022 $ 991,941 $ 84,070 2021 Supplemental pro forma from January 1, 2021 to March 31, 2021 $ 495,081 $ (2,651,152 ) The 2021 Supplemental pro forma earnings information was adjusted to account for amortization of intangibles on acquisition of $89,495. |
Due on sale of business
Due on sale of business | 3 Months Ended |
Mar. 31, 2022 | |
Due On Sale Of Business | |
Due on sale of business | 5. Due on sale of business On February 14, 2017, the Company sold its Canadian Rehab Clinic for gross proceeds of CDN$10,000,000, of which CDN$1,500,000 had been retained in an escrow account for a period of up to two years in order to guarantee the warranties provided by the Company in terms of the APA. As of March 31, 2022, CDN$1,055,042 of the escrow had been refunded to the Company and CDN$461,318 had been used to affect building improvements to the premises owned by CCH, for a total reduction of CDN$1,516,360. The remaining escrow balance was CDN$6,485 (approximately US$ 5,190). |
Property and equipment
Property and equipment | 3 Months Ended |
Mar. 31, 2022 | |
Property, Plant and Equipment [Abstract] | |
Property and equipment | 6. Property and equipment Property and equipment consists of the following: Schedule of sale of property March 31, December 31, 2021 Cost Accumulated depreciation Net book value Net book value Land $ 172,055 $ — $ 172,055 $ 168,585 Property 3,254,757 (652,897 ) 2,601,860 2,596,590 Leasehold improvements 237,015 (17,718 ) 219,297 153,730 Furniture and fittings 53,556 (11,589 ) 41,967 42,140 Vehicles 55,949 (9,478 ) 46,471 49,268 Computer equipment 1,450 (222 ) 1,228 1,350 $ 3,774,782 $ (691,904 ) $ 3,082,878 $ 3,012,663 Depreciation expense for the three months ended March 31, 2022 and 2021 was $ 132,000 32,125 |
Intangibles
Intangibles | 3 Months Ended |
Mar. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangibles | 7. Intangibles Intangible assets consist of the Company’s preliminary estimate of the fair value of intangibles acquired with the acquisition of ATHI disclosed in Note 4 above. The Company preliminarily allocated the excess over the tangible assets acquired, less the liabilities assumed to the contract provided to the Company by a health care service provider. Intangible assets consist of the following: Schedule of Intangible assets March 31, 2022 December 31, 2021 Cost Accumulated amortization Net book value Net book value Health care Provider license $ 1,789,903 $ (268,485 ) $ 1,521,418 $ 1,610,913 The Company evaluates intangible assets for impairment on an annual basis during the last month of each year and at an interim date if indications of impairment exist. Intangible asset impairment is determined by comparing the fair value of the asset to its carrying amount with an impairment being recognized only when the fair value is less than carrying value and the impairment is deemed to be permanent in nature. The Company recorded $ 89,495 |
Leases
Leases | 3 Months Ended |
Mar. 31, 2022 | |
Leases [Abstract] | |
Leases | 8. Leases Right of use assets are included in the condensed consolidated balance sheet are as follows: Schedule of Right of use assets March 31, 2022 December 31, Non-current assets Right-of-use assets – finance leases, net of depreciation, included in Property and equipment $ 46,471 $ 49,268 Right-of-use assets - operating leases, net of amortization $ 1,590,752 $ 1,653,816 Lease costs consists of the following: Schedule of Lease costs Three months ended March 31, 2022 2021 Finance lease cost: Amortization of right-of-use assets $ 2,797 $ — Interest expense on finance lease liabilities 648 — Finance lease cost 3,445 — Operating lease cost $ 63,064 $ — Lease cost $ 63,064 $ — Other lease information: Schedule of Other lease Three months ended March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from finance leases $ (1,809 ) $ — Operating cash flows from operating leases (63,064 ) — $ (64,873 ) $ — Weighted average lease term – finance leases 4 years and seven months — Weighted average remaining lease term – operating leases 4 years and 10 months — Discount rate – finance leases 6.61 % — Discount rate – operating leases 4.64 % — Maturity of Leases Finance lease liability The amount of future minimum lease payments under finance leases as of March 31, 2022 is as follows: Schedule of Finance lease liability Amount Remainder of 2022 $ 7,372 2023 9,829 2024 9,829 2025 9,829 2026 7,902 Total undiscounted minimum future lease payments 44,761 Imputed interest (6,303 ) Total finance lease liability $ 38,458 Disclosed as: Current portion $ 7,507 Non-Current portion 30,951 Lease liability $ 38,458 Operating lease liability The amount of future minimum lease payments under operating leases are as follows: Schedule of Operating lease liability Amount Remainder of 2022 $ 250,047 2023 348,677 2024 366,110 2025 384,416 2026 437,407 Total undiscounted minimum future lease payments 1,786,657 Imputed interest (109,299 ) Total operating lease liability $ 1,677,358 Disclosed as: Current portion $ 254,340 Non-Current portion 1,425,018 Lease liability $ 1,677,358 |
Taxes Payable
Taxes Payable | 3 Months Ended |
Mar. 31, 2022 | |
Taxes Payable | |
Taxes Payable | 9. Taxes Payable The taxes payable consist of: ● A payroll tax liability of $146,119 (CDN$182,589) in Greenstone Muskoka which has not been settled as yet. ● A GST/HST tax payable of $137,200 (CDN$171,445). Schedule of taxation payable March 31, December 31, Payroll taxes $ 146,119 $ 144,020 HST/GST payable 137,200 123,134 Income tax payable 434,346 391,682 Taxes Payable $ 717,665 $ 658,836 |
Short-term Convertible Notes
Short-term Convertible Notes | 3 Months Ended |
Mar. 31, 2022 | |
Debt Disclosure [Abstract] | |
Short-term Convertible Notes | 10. Short-term Convertible Notes The short-term convertible notes consist of the following: Schedule of short-term convertible notes Interest rate Maturity Date Principal Interest Debt Discount March 31, 2022 December 31, 2021 Leonite Capital, LLC 12.0 % On Demand $ 129,379 $ 43,673 $ — $ 173,052 $ 315,579 Auctus Fund, LLC 0.0 % On Demand 80,000 — — 80,000 100,000 Labrys Fund, LP 12.0 % November 30, 2021 — 8,826 — 8,826 8,826 11.0 % May 7, 2022 389,045 — (75,420 ) 313,625 354,504 11.0 % June 2, 2022 230,000 20,074 (47,942 ) 202,132 148,488 Ed Blasiak 6.5 % September 14, 2021 55,000 5,591 — 60,591 59,697 Joshua Bauman 11.0 % October 21, 2022 150,000 7,278 (83,836 ) 73,442 32,387 Geneva Roth Remark Holdings, Inc. 8.0 % October 1, 2022 42,311 3,385 (21,329 ) 24,367 24,384 Series N convertible notes 6.0 % On Demand 3,229,000 666,845 — 3,895,845 3,848,073 $ 4,304,735 $ 755,672 $ (228,527 ) $ 4,831,880 $ 4,891,938 Leonite Capital, LLC On July 12, 2020, the Company entered into a Senior Secured Convertible Note agreement with Leonite for $440,000 with an original issue discount of $40,000 for gross proceeds of $400,000, the initial tranche advanced will be for cash of $200,000 plus the OID of $20,000, the remaining advances will be at the discretion of the Leonite. The loan bears interest at 6.5% per annum and matures on June 12, 2021. The Company is required to make monthly payments of the accrued interest on the advances made. The note is convertible into common shares at the option of the holder at $0.10 per share, or 80% multiplied by the price per share paid in subsequent financings or after a six month period from the effective date at 60% of the lowest trading price during the preceding 21 consecutive trading days. The note has both conversion price protection and anti-dilution protection provisions. In terms of clause 3.12 of the Senior secured convertible Promissory Note Agreement (“Leonite Note”) entered into with Leonite and the amendments thereto, the terms of the convertible promissory note issued to Labrys Fund LP on November 30, 2020, as described below, contained terms more favorable than those contained in the Leonite Note, resulting in an adjustment made to the Original issue discount of $4,000 and the issuance of five year warrants exercisable for 145,454,547 shares of common at an exercise price of $0.00205 per share, for all advances made to the Company by Leonite in terms of the Leonite Note, up to and including December 31, 2020. On January 8, January 22, February 4, and February 19, 2021, Leonite advanced the company an aggregate cash amount of $290,000, including a revised original issue discount of $74,556 for an aggregate principal sum added to the Leonite Note of $364,556. On March 3, 2021, in terms of a conversion notice, Leonite converted the principal sum of $82,681 and interest thereon of $12,319 of the Leonite Note into 97,000,000 shares of common stock at a conversion price of $0.0009 per share. On June 1, 2021, in terms of a conversion notice, Leonite converted the principal sum of $25,084 and interest thereon of $4,166 of the Leonite Note into 30,000,000 shares of common stock at a conversion price of $0.0009 per share. On June 10, 2021, in terms of a conversion notice, Leonite converted the principal sum of $58,908 and interest thereon of $342 of the Leonite Note into 60,000,000 shares of common stock at a conversion price of $0.0009 per share. On September 10, 2021, in terms of a conversion notice, Leonite converted the principal sum of $59,260 and interest thereon of $1,718 of the Leonite Note into 59,259,630 shares of common stock at a conversion price of $0.0010 per share. On October 19, 2021, in terms of a conversion notice, Leonite converted the principal sum of $44,444 and interest thereon of $5,302 of the Leonite Note into 50,496,728 shares of common stock at a conversion price of $0.0010 per share. On October 29, 2021, the Company issued 83,771,947 shares of common stock to Leonite in connection with a conversion notice received, converting principal and interest of $83,022 at a conversion price of $0.0009 per share. On November 22, 2021, in terms of a conversion notice, Leonite converted the principal sum of $50,532 and interest thereon of $7,145 of the Leonite Note into 58,427,091 shares of common stock at a conversion price of $0.0010 per share. On December 13, 2021, in terms of a conversion notice, Leonite converted the principal sum of $89,684 and interest thereon of $249 of the Leonite Note into 90,682,696 shares of common stock at a conversion price of $0.0010 per share. On February 28, 2022, in terms of a conversion notice, Leonite converted the principal sum of $149,250 of the Leonite Note into 150,000,000 shares of common stock at a conversion price of $0.0010 per share. Auctus Fund, LLC On August 7 2019, the Company, entered into a Securities Purchase Agreement with Auctus Fund, LLC, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $225,000. The Note had a maturity date of May 7, 2020 and bore interest at the rate of ten percent per annum from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company had the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note is convertible at any time and from time to time at the election of Auctus Fund, LLC during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to 60% of the lowest closing bid price of the Company’s common stock for the thirty trading days prior to conversion. On June 15, 2020, The Company entered into an amended agreement with Auctus whereby the Company agreed to discharge the principal amount of the note by nine equal monthly installments of $25,000 commencing in October 2020. During the year ended December 31, 2021, the Company repaid Auctus the principal sum of $50,000. During March 2022, the Company paid $20,000 of principal on the convertible note, thereby reducing the principal outstanding to $80,000. The note matured May 7, 2020, Auctus Fund LLC has not declared a default and we are in constant discussion with the lender on settling the note. Labrys Fund, LP On November 30, 2020, the Company, entered into a Securities Purchase Agreement with Labrys, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $275,000 for net proceeds of $239,050 after an original issue discount of $27,500 and certain legal expenses. The Note has a maturity date of November 30, 2021 and bears interest at the rate of twelve percent per annum from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company has the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note was convertible at any time and from time to time at the election of Labrys during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to 60% of the lowest closing bid price of the Company’s common stock for the thirty trading days prior to conversion. On May 3, 2021, in terms of a conversion notice received by the company, Labrys converted the aggregate principal sum of $57,000 including interest thereon of $33,000 into 100,000,000 shares of common stock. On July 7, 2021, in terms of a conversion notice received by the company, Labrys converted the aggregate principal sum of $100,800 into 112,000,000 shares of common stock. On September 28, 2021, in terms of a conversion notice received by the company, Labrys converted the aggregate principal sum of $54,000 into 60,000,000 shares of common stock. On October 8, 2021, in terms of a conversion notice received by the company, Labrys converted the aggregate principal sum of $55,800 into 62,000,000 shares of common stock. On October 15, 2021, in terms of a conversion notice received by the company, Labrys converted the aggregate principal sum of $7,400 into 8,222,222 shares of common stock. The Company has $8,826 of interest outstanding under the convertible promissory note. On May 7, 2021, the Company, entered into a Securities Purchase Agreement with Labrys, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $550,000 for net proceeds of $477,700 after an original issue discount of $55,000 and certain legal expenses of $17,300. The Note has a maturity date of May 7, 2022 and bears interest at the rate of eleven percent per annum from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company has the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note was convertible at any time and from time to time at the election of Labrys during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to $0.005, subject to anti-dilution adjustments. On November 23, 2021, in terms of a conversion notice received by the company, Labrys converted the aggregate principal sum of $6,329 and interest of $60,500 into 75,000,000 shares of common stock. Effective December 29, 2021, the Company entered into a modification of the convertible note agreement with Labrys whereby the May 7, 2021 note were amended as follows: · The Maturity date of the note was extended to May 31, 2022. · The triggering of the dilutive event on October 25, 2021 which reduced the conversion price of the convertible note to $0.001 per share, will not be utilized as long as any events of default under the note are not triggered. · The Company agreed to make monthly payments under the note totaling $536,000 between January 10, and May 31, 2022. During the three months ended March 31, 2022, the Company repaid $150,000 of the outstanding principal of the convertible note. There have been no further events of default in terms of this convertible note and we are in discussion with the note holder on settling the note. On June 2, 2021, the Company, entered into a Securities Purchase Agreement with Labrys, pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $230,000 for net proceeds of $200,000 after an original issue discount of $23,000 and certain legal expenses of $7,000. The Note has a maturity date of June 2, 2022 and bears interest at the rate of eleven percent per annum from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company has the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note was convertible at any time and from time to time at the election of Labrys during the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to $0.004, subject to anti-dilution adjustments. Effective December 29, 2021, the Company entered into a modification of the convertible note agreement with Labrys whereby the May 7, 2021 note were amended as follows: · The Maturity date of the note was extended to June 30, 2022. · The triggering of the dilutive event on October 25, 2021 which reduced the conversion price of the convertible note to $0.001 per share, will not be utilized as long as any events of default under the note are not triggered. · The Company agreed to make two equal payments of $127,650 on the note on May 31, and June 30, 2022. The note is not in default and we are in discussions with the lender on settling the outstanding balance on this note. Ed Blasiak On September 14, 2020, the Company entered into a Securities Purchase Agreement with Ed Blasiak (“Blasiak”), pursuant to which the Company issued a senior secured convertible promissory note in the aggregate principal amount of $55,000, including an original issue discount of $5,000. The note bears interest at 6.5% per annum and matures on September 14, 2021. The note is senior to any future borrowings and commencing on October 1, 2020 the Company will make monthly payments of the accrued interest under the note. The note may be prepaid at certain prepayment penalties and is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions; or 80% of the price per share of subsequent equity financings or; after six months 60% of the lowest trading price during the preceding six month period. The note has matured, Ed Blasiak has not declared a default under the note and we are in communication with Mr. Blasiak on our ability to repay the note. Joshua Bauman On September 14, 2020, the Company entered into a Securities Purchase Agreement with Joshua Bauman (“Bauman”), pursuant to which the Company issued a senior secured convertible promissory note in the aggregate principal amount of $110,000, including an original issue discount of $10,000. The note bears interest at 6.5% per annum and matures on September 14, 2021. The note is senior to any future borrowings and commencing on October 1, 2020 the Company will make monthly payments of the accrued interest under the note. The note may be prepaid at certain prepayment penalties and is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions; or 80% of the price per share of subsequent equity financings or; after six months 60% of the lowest trading price during the preceding six month period. On June 8, 2021, in terms of a conversion notice received by the company, Bauman converted the aggregate principal sum of $100,000 including interest thereon of $5,563 into 106,313,288 shares of common stock. On October 25, 2021, in terms of a conversion notice received by the company, Bauman converted the aggregate principal sum of $37,500 including interest thereon of $1,155 into 39,405,310 shares of common stock, thereby extinguishing the note. On October 21, 2021, the Company entered into a Securities Purchase Agreement with Joshua Bauman (“Bauman”), pursuant to which the Company issued a senior secured convertible promissory note in the aggregate principal amount of $150,000, including an original issue discount of $16,250. The note bears interest at 11.0% per annum, which is guaranteed and earned in full on issue date and matures on October 21, 2022. The note may be prepaid at certain prepayment penalties and is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions. Geneva Roth Remark Holdings, Inc On October 1, 2021, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory Note in the aggregate principal amount of $95,200, for net proceeds of $85,000 before the payment of legal fees and origination fees amounting to $3,750. The note has a maturity date of October 1, 2022 and bears interest at the rate of 8.0% per annum, due immediately on the issuance date of the note. The outstanding principal amount of the note is payable in nine monthly payments of $11,424 commencing on November 15, 2021. The note is convertible into shares of common stock upon an event of default at the election of the purchaser. The conversion price is 75% of the lowest trading price for the preceding five days prior to the date of conversion. Series N convertible notes Between January 28, 2019 and June 11, 2020, the Company closed several tranches of Series N Convertible notes in which it raised $3,229,000 in principal from accredited investors through the issuance to the investors of the Company’s Series N convertible notes, in the total original principal amount of $3,229,000, which Notes are convertible into the Company’s common stock at a conversion price of $0.08 per share together with three year warrants to purchase up to a total of 52,237,500 shares of the Company’s common stock at an exercise price of $0.12 per share. Both the conversion price under the Notes and the exercise price under the warrants are subject to standard adjustment mechanisms. The notes matured one year from the date of issuance. The series N convertible notes have past their maturity date, there are no default terms and we are considering our options to settle these notes. |
hort term loans
hort term loans | 3 Months Ended |
Mar. 31, 2022 | |
Debt Disclosure [Abstract] | |
hort term loans | 11. S hort term loans LXR Biotech On April 12, 2019, the Company, entered into a secured Promissory Note in the aggregate principal amount of CDN$133,130. The Note had a maturity date of April 11, 2020 and bears interest at the rate of six percent per annum from the date on which the Note was issued. This note has not been repaid as yet and remains outstanding. Leonite Capital, LLC Secured Promissory Notes On March 1, 2022, the Company entered into a secured Promissory Note in the aggregate principal amount of $124,000 for net proceeds of $100,000 after an original issue discount of $24,000. The Note had a maturity date of April 1, 2022. This note has not been repaid at the date of this report and no default has been declared. We are in discussions with Leonite on the repayment of this note and the advancement of additional funds for business purposes. |
Mortgage loans
Mortgage loans | 3 Months Ended |
Mar. 31, 2022 | |
Mortgage Loans | |
Mortgage loans | 12. Mortgage loans Mortgage loans is disclosed as follows: Schedule of mortgage loans Interest Maturity Principal Accrued March 31, December 31, Cranberry Cove Holdings, Ltd. Pace Mortgage 4.2 % July 19, 2022 $ 3,884,941 $ 5,365 $ 3,890,306 $ 3,864,312 Disclosed as follows: Short-term portion $ 3,890,306 $ 3,864,312 Cranberry Cove Holdings, Ltd. On July 19, 2017, CCH, a wholly owned subsidiary, closed on a loan agreement in the principal amount of CDN$5,500,000. The loan is secured by a first mortgage on the premises owned by CCH located at 3571 Muskoka Road 169, Bala, Ontario. The loan bears interest at the fixed rate of 4.2% with a 5-year primary term and a 25-year amortization. The Company has guaranteed the loan and the Company’s chief executive officer and controlling shareholder also has personally guaranteed the Loan. CCH and the Company have granted the Lender a general security interest in its assets to secure repayment of the Loan. The loan is amortized with monthly installments of CDN $29,531. |
Government assistance loans
Government assistance loans | 3 Months Ended |
Mar. 31, 2022 | |
Government Assistance Loans | |
Government assistance loans | 13. Government assistance loans On December 1, 2020, CCH was granted a Covid-19 related government assistance loan in the aggregate principal amount of CDN$ 40,000 (Approximately $31,000). the grant is interest free and CDN$ 10,000 is forgivable if the loan is repaid in full by December 31, 2022. On January 12, 2021, CCH received a further CDN$ Covid-19 related government assistance loan. The loan is interest free and if repaid by December 31, 2022, CDN$ is forgivable. On May 3, 2021, the Company was granted a government assistance loan in the aggregate principal amount of $157,367. The loan is forgivable if the Company demonstrates that the proceeds were used for expenses such as employee costs during the pandemic. Should the loan not be forgiven, interest is payable on the loan at the rate of 1% per annum and the principal is repayable and interest is payable over an 18 month period. No payments have been made to date and the Company expects the loan to be forgiven, therefore no interest has been accrued. The company has applied for forgiveness of this government assistance loan, we expect that the loan will be forgiven and are awaiting written confirmation of forgiveness. |
Third party loans
Third party loans | 3 Months Ended |
Mar. 31, 2022 | |
Third Party Loans | |
Third party loans | 14. Third party loans On April 12, 2019, Eileen Greene, a related party assigned CDN$1,000,000 of the amount owed by the Company to her, to a third party. The loan bears interest at 12% per annum which the Company agreed to pay. During the current period the Company repaid CDN$100,000 (approximately $78,977). |
Derivative liability
Derivative liability | 3 Months Ended |
Mar. 31, 2022 | |
Derivative Liability | |
Derivative liability | 15. Derivative liability The short-term convertible notes issued to convertible note holders disclosed in note 10 above, have variable priced conversion rights with no fixed floor price and will reprice dependent on the share price performance over varying periods of time. This gives rise to a derivative financial liability, which was initially valued at inception of the convertible notes at $1,959,959 using a Black-Scholes valuation model. The derivative liability is marked-to-market on a quarterly basis. As of March 31, 2022, the derivative liability was valued at $ 278,699 The following assumptions were used in the Black-Scholes valuation model: Schedule of assumption used in Black Scholes Three months ended Calculated stock price $ 0.0006 0.0010 Risk free interest rate 0.06 2.45 % Expected life of convertible notes and warrants 3 39 expected volatility of underlying stock 167.1 238.1 % Expected dividend rate 0 % The movement in derivative liability is as follows: Schedule of derivative liability March 31, December 31, Opening balance $ 515,901 $ 4,765,387 Derivative liability extinguished on convertible notes converted to equity (39,726 ) (2,914,119 ) Derivative liability on issued convertible notes — 190,824 Fair value adjustments to derivative liability (197,476 ) (1,526,191 ) Closing balance $ 278,699 $ 515,901 |
Related party transactions
Related party transactions | 3 Months Ended |
Mar. 31, 2022 | |
Related Party Transactions [Abstract] | |
Related party transactions | 16. Related party transactions Shawn E. Leon As of March 31, 2022 and December 31, 2021 the Company had a payable to Shawn Leon of $ 341,379 106,100 Due to the current financial position of the Group, Mr. Leon forfeited the management fees due to him for the three months ended March 31, 2022 and the year ended December 31, 2021. Leon Developments, Ltd. As of March 31, 2022 and December 31, 2021, the Company owed Leon Developments, Ltd., $ 955,398 935,966 Eileen Greene As of March 31, 2022 and December 31, 2021, the Company owed Eileen Greene, the spouse of our CEO, Shawn Leon, $ 1,496,164 1,472,215 All related party transactions occur in the normal course of operations and in terms of agreements entered into between the parties. |
Stockholder_s deficit
Stockholder’s deficit | 3 Months Ended |
Mar. 31, 2022 | |
Equity [Abstract] | |
Stockholder’s deficit | 17. Stockholder’s deficit a) Common shares Authorized and outstanding The Company has authorized 10,000,000,000 shares with a par value of $0.01 per share. The company has issued and outstanding 3,729,053,805 and 3,579,053,805 shares of common stock at March 31, 2022 and December 31, 2021, respectively. On February 28, 2022, the Company issued 150,000,000 shares of common stock to Leonite in connection with a conversion notice received, converting principal of $149,250. b) Series A Preferred shares Authorized, issued and outstanding The Company has authorized 10,000,000 Series A preferred shares with a par value of $0.01 per share. The company has issued and outstanding 4,000,000 Series A Preferred shares at March 31, 2022 and December 31, 2021, respectively. c) Series B Preferred shares Authorized and outstanding The Company has authorized 400,000 Series B preferred shares with a par value of $1.00 per share. The company has issued and outstanding 400,000 Series B Preferred shares at March 31, 2022 and December 31, 2021, respectively. d) Stock options Our board of directors adopted the Greenstone Healthcare Corporation 2013 Stock Option Plan (the “Plan”) to promote our long-term growth and profitability by (i) providing our key directors, officers and employees with incentives to improve stockholder value and contribute to our growth and financial success and (ii) enable us to attract, retain and reward the best available persons for positions of substantial responsibility. A total of 10,000,000 shares of our common stock have been reserved for issuance upon exercise of options granted pursuant to the Plan. The Plan allows us to grant options to our employees, officers and directors and those of our subsidiaries; provided that only our employees and those of our subsidiaries may receive incentive stock options under the Plan. We have no issued options at March 31, 2022 under the Plan. e) Warrants All of the warrants with the exception of the 8,287,500 warrants exercisable at $0.12 per share have cashless exercise terms whereby in-the-money warrants may be exercised by reducing the number of shares issued in terms of the warrant exercise to offset the proceeds due on the exercise. The 8,287,500 warrants are only exercisable for cash. All of the warrants with the exception of the 8,287,500 warrants exercisable at $0.12 per share have price protection features whereby any securities issued subsequent to the date of the warrant issuance date, were issued at a lower price, or have conversion features that are lower than the current exercise price, or were converted at a lower price, or are exercisable at a lower price, to the current warrant exercise price, will result in the exercise price of the warrant being set to the lower issue, conversion or exercise price. A summary of the Company’s warrant activity during the period from January 1, 2021 to March 31, 2022 is as follows: Schedule of warrants outstanding No. of shares Exercise price Weighted Outstanding as of January 1, 2021 615,561,379 $0.000675 to $0.12 $ 0.011380 Granted 471,010,103 $0.0020500 0.003080 Forfeited/cancelled (101,682,866 ) $0.0015 to $0.12 0.039029 Exercised (361,111,110 ) $0.00150 to $0.00205 0.003291 Outstanding as of December 31, 2021 623,777,506 $0.000675 to $0.12 $ 0.0052875 Granted — — — Forfeited/cancelled (12,637,500 ) $0.12 0.12 Exercised — — — Outstanding as of March 31, 2022 611,140,006 $0.000675 to $0.12 $ 0.0029154 The following table summarizes information about warrants outstanding at March 31, 2022: Schedule of assumption Warrants outstanding Warrants exercisable Exercise price No. of shares Weighted average remaining years Weighted average exercise price No. of shares Weighted average exercise price $0.000675 326,286,847 3.28 326,286,847 $0.002050 276,565,659 3.77 276,565,659 $0.120000 8,287,500 0.27 8,287,500 611,140,006 3.46 $ 0.0029154 611,140,006 $ 0.0029154 All of the warrants outstanding at March 31, 2022 are vested. The warrants outstanding at March 31, 2022 have an intrinsic value of $8,157. |
Segment information
Segment information | 3 Months Ended |
Mar. 31, 2022 | |
Segment Information | |
Segment information | 18. Segment information The Company has two reportable operating segments: a. Rental income from the property owned by CCH subsidiary located at 3571 Muskoka Road, #169, Bala, on which the operations of the Canadian Rehab Clinic were located prior to disposal on February 14, 2017 and subsequently leased to the purchasers of the business of the Canadian Rehab Clinic, for a period of 5 years renewable for a further three five-year periods and with an option to acquire the property at a fixed price. b. Rehabilitation Services provided to customers, these services were provided to customers at our Evernia, Addiction Recovery Institute of America and Seastone of Delray operations. The segment operating results of the reportable segments for the three months ended March 31, 2022 is disclosed as follows: Schedule of segment information Three months ended March 31, 2022 Rental In-Patient Total Revenue $ 93,874 $ 929,441 $ 1,023,315 Operating expenses (33,316 ) (915,059 ) (948,375 ) Operating income 60,558 14,382 74,940 Other (expense) income Other income — 10,018 10,018 Interest expense (53,607 ) (27,161 ) (80,768 ) Amortization of debt discount — (252,832 ) (252,832 ) Derivative liability movement — 197,476 197,476 Foreign exchange movements (21,829 ) (73,727 ) (95,556 ) Net loss before taxes (14,878 ) (131,844 ) (146,722 ) Taxes — (18,263 ) (18,263 ) Net loss $ (14,878 ) $ (150,107 ) $ (164,985 ) The operating assets and liabilities of the reportable segments as of March 31, 2022 is as follows: March 31, 2022 Rental In-Patient Total Purchase of fixed assets $ — $ 72,858 $ 72,858 Assets Current assets 551 355,167 355,718 Non-current assets 2,773,914 3,426,324 6,200,238 Liabilities Current liabilities (1,590,715 ) (12,078,894 ) (13,669,609 ) Non-current liabilities (636,577 ) (1,710,232 ) (2,346,809 ) Mandatory redeemable preferred shares — (400,000 ) (400,000 ) Intercompany balances 1,238,399 (1,238,399 ) — Net liability position $ 1,785,572 $ (11,646,034 ) $ (9,860,462 ) Three months ended March 31, 2021 Rental Operations In-Patient services Total Revenue $ 90,793 $ — $ 90,793 Operating expenditure (32,849 ) (19,167 ) (52,016 ) Operating income (loss) 57,944 (19,167 ) 38,777 Other (expense) income Penalty on convertible notes — (9,240 ) (9,240 ) Fair value of warrants granted — (976,788 ) (976,788 ) Fair value of warrants exercised — (90,000 ) (90,000 ) Interest expense (59,745 ) (77,932 ) (137,677 ) Amortization of debt discount — (502,677 ) (502,677 ) Derivative liability movement — (611,059 ) (611,059 ) Foreign exchange movements (18,695 ) (60,797 ) (79,492 ) Net loss before taxation (20,496 ) (2,347,660 ) (2,368,156 ) Taxation — — — Net loss $ (20,496 ) $ (2,347,660 ) $ (2,368,156 ) The operating assets and liabilities of the reportable segments as of March 31, 2021 is as follows: March 31, 2021 Rental Operations In-Patient services Total Purchase of fixed assets $ — $ — $ — Assets Current assets 4,580 1,196,939 1,201,519 Non-current assets 2,885,861 5,157 2,891,018 Liabilities Current liabilities (1,484,968 ) (12,388,857 ) (13,873,825 ) Non-current liabilities (4,645,209 ) — (4,645,209 ) Mandatory redeemable preferred shares — (400,000 ) (400,000 ) Intercompany balances 1,330,423 (1,330,423 ) — Net liability position $ (1,909,313 ) $ (12,917,184 ) $ (14,826,497 ) |
Net (loss) income per common sh
Net (loss) income per common share | 3 Months Ended |
Mar. 31, 2022 | |
Earnings Per Share [Abstract] | |
Net (loss) income per common share | 19. Net (loss) income per common share For the three months ended March 31, 2022 and 2021, the following options, warrants and convertible securities were excluded from the computation of diluted net loss per share as the results would have been anti-dilutive. Schedule of Antidilutive Securities Three months ended Three months ended Warrants to purchase shares of common stock 611,140,006 926,470,474 Convertible notes 458,435,448 662,500,729 1,069,575,454 1,588,971,203 |
Commitments and contingencies
Commitments and contingencies | 3 Months Ended |
Mar. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and contingencies | 20. Commitments and contingencies a. Options granted to purchase shares in ATHI On July 12, 2020, the Company entered into a five year option agreement with Leonite Capital LLC (“Leonite”) and other investors (collectively the “Transferees”), the Company agreed to sell to Leonite a portion of the total outstanding shares of ATHI from the shares of ATHI held by the company. The Company provided Leonite an option to purchase 4,000,000 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $400), based on the advances that Leonite made to the Company totaling $396,000. Leonite shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Leonite to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option. On September 14, 2020, the Company entered into a five year option agreement with Ed Blasiak (“Blasiak”) whereby the Company agreed to sell to Blasiak a portion of the total outstanding shares of ATHI. The Company provided Blasiak an option to purchase 571,428 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $57), based on the advances that Blasiak made to the Company totaling $50,000. Blasiak shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Blasiak to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option. On October 29, 2020, the Company entered into a five year option agreement with First Fire whereby the Company agreed to sell to First Fire a portion of the total outstanding shares of ATHI. The Company provided First Fire an option to purchase 1,428,571 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $143), based on the advances that First Fire made to the Company totaling $120,000. First Fire shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by First Fire to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option. On October 29, 2020, the Company entered into a five year option agreement entered into with Bauman, so that the Company agreed to sell to Bauman a portion of the total outstanding shares of ATHI. The Company provided Bauman an option to purchase 1,428,571 shares of ATHI from the Company for a purchase consideration of $0.0001 per share (a total consideration of $143), based on the advances that Bauman made to the Company totaling $120,000. Bauman shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Bauman to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option. b. Mortgage loans The company has a mortgage loan as disclosed in note 12 above. The mortgage loan matures on July 19, 2022 and the Company currently owes $3,890,306. c. Other The Company has principal and interest payment commitments under the Convertible notes disclosed under Note 10 above. Conversion of these notes are at the option of the investor, if not converted these notes may need to be repaid. From time to time, the Company and its subsidiaries enter into legal disputes in the ordinary course of business. The Company believes there are no material legal or administrative matters pending that are likely to have, individually or in the aggregate, a material adverse effect on its business or results of operations. |
Subsequent events
Subsequent events | 3 Months Ended |
Mar. 31, 2022 | |
Subsequent Events [Abstract] | |
Subsequent events | 21. Subsequent events On May 3, 2022, the Company, entered into a secured Promissory Note in the aggregate principal amount of $76,250 for net proceeds of $61,000 after an original issue discount of $15,250. The Note had a maturity date of June 17, 2022 and bears interest at the rate of zero percent per annum from the date on which the Note was issued until the same became due and payable. Other than disclosed above, the Company has evaluated subsequent events through the date of the condensed consolidated financial statements were issued, we did not identify any other subsequent events that would have required adjustment or disclosure in the financial statements. |
Summary of significant accoun_2
Summary of significant accounting policies (Policies) | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Use of Estimates | a) Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. These estimates and assumptions include valuing equity securities issued in share-based payment arrangements, determining the fair value of assets acquired, allocation of purchase price, impairment of long-lived assets, the collectability of receivables, leasing arrangements, convertible debentures, contingencies and the value of deferred taxes and related valuation allowances. Certain estimates, including evaluating the collectability of receivables and advances, could be affected by external conditions, including those unique to the Company’s industry and general economic conditions. It is possible that these external factors could have an effect on the Company’s estimates that could cause actual results to differ from the Company’s estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and record adjustments when necessary. |
Principals of consolidation and foreign currency translation | b) Principals of consolidation and foreign currency translation The accompanying condensed consolidated financial statements include the accounts of the Company and all of its subsidiaries. ATHI and its wholly owned subsidiary Evernia, have been consolidated since July 1, 2021. All intercompany transactions and balances have been eliminated on consolidation. Certain of the Company’s subsidiaries functional currency is the Canadian dollar, while the Company’s reporting currency is the U.S. dollar. All transactions initiated in Canadian dollars are translated into US dollars in accordance with ASC 830, “Foreign Currency Translation” as follows: ● Monetary assets and liabilities at the rate of exchange in effect at the balance sheet date. ● Non-monetary, non-current and equity at historical rates. ● Revenue and expense items and cash flows at the average rate of exchange prevailing during the period. Adjustments arising from such translations are deferred until realization and are included as a separate component of stockholders’ deficit as a component of accumulated other comprehensive income or loss. Therefore, translation adjustments are not included in determining net income (loss) but reported as other comprehensive income (loss). For foreign currency transactions, the Company translates these amounts to the Company’s functional currency at the exchange rate effective on the invoice date. If the exchange rate changes between the time of purchase and the time actual payment is made, a foreign exchange transaction gain or loss results which is included in determining net income for the period. The relevant translation rates are as follows: For the three months ended March 31, 2022, a closing rate of CDN$1.0000 equals US$0.8003 and an average exchange rate of CDN$1.0000 equals US$0.78980. For the three months ended March 31, 2021, a closing rate of CAD$1.0000 equals US$0.7952 and an average exchange rate of CAD$1.0000 equals US$0.7899. |
Business Combinations | c) Business Combinations The Company allocates the fair value of purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired users, acquired technology, and trade names from a market participant perspective, useful lives and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. |
Cash and cash equivalents | d) Cash and cash equivalents For purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with several financial institutions in the USA and Canada. The Company primarily places cash balances in the USA with high-credit quality financial institutions located in the United States which are insured by the Federal Deposit Insurance Corporation up to a limit of $250,000 per institution, in Canada which are insured by the Canadian Deposit Insurance Corporation up to a limit of CDN$100,000 per institution. |
Accounts receivable | e) Accounts receivable Accounts receivable primarily consists of amounts due from third-party payors (non-governmental) and private pay patients and is recorded net of allowances for doubtful accounts and contractual discounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s consolidated financial statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimating net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies denying claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients. |
Allowance for Doubtful Accounts, Contractual and Other Discounts | f) Allowance for Doubtful Accounts, Contractual and Other Discounts The Company derives the majority of its revenues from commercial payors at in-network rates. Management estimates the allowance for contractual and other discounts based on its historical collection experience. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account is written off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made. |
Property and equipment | g) Property and equipment Property and equipment is recorded at cost. Depreciation is calculated on the straight line basis over the estimated life of the asset. |
Intangible assets | h) Intangible assets Intangible assets are stated at acquisition cost less accumulated amortization, if applicable, less any adjustments for impairment losses. Amortization is charged on a straight-line basis over the estimated remaining useful lives of the individual intangibles. Where intangibles are deemed to be impaired the Company recognizes an impairment loss measured as the difference between the estimated fair value of the intangible and its book value. Licenses to provide substance abuse rehabilitation services are amortized over the expected life of the contract, including any anticipated renewals. The Company expects its licenses to remain in operation for a period of five years. |
Leases | i) Leases The Company accounts for leases in terms of AC 842 whereby leases are classified as either capital or operating leases. Leases that transfer substantially all of the benefits and inherent risks of ownership of property to the Company are accounted for as capital leases. At the time a capital lease is entered into, an asset is recorded together with its related long-term obligation to reflect the acquisition and financing. Equipment recorded under capital leases is amortized on the same basis as described above. Operating leases are recognized on the balance sheet as a lease liability with a corresponding right of use asset for all leases with a term that is more than twelve months. Payments under operating leases are expensed as incurred. |
Derivatives | j) Derivatives The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. The Company uses a Black Scholes Option Pricing model to estimate the fair value of convertible debt conversion features at the end of each applicable reporting period. Changes in the fair value of these derivatives during each reporting period are included in the statements of operations. Inputs into the Black Scholes Option Pricing model require estimates, including such items as estimated volatility of the Company’s stock, risk free interest rate and the estimated life of the financial instruments being fair valued. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options” for consideration of any beneficial conversion feature. |
Financial instruments | k) Financial instruments The Company initially measures its financial assets and liabilities at fair value, except for certain non-arm’s length transactions. The Company subsequently measures all its financial assets and financial liabilities at amortized cost. Financial assets measured at amortized cost include cash and accounts receivable. Financial liabilities measured at amortized cost include bank indebtedness, accounts payable and accrued liabilities, harmonized sales tax payable, withholding taxes payable, convertible notes payable, loans payable and related party notes. Financial assets measured at cost are tested for impairment when there are indicators of impairment. The amount of the write-down is recognized in net income. The previously recognized impairment loss may be reversed to the extent of the improvement, directly or by adjusting the allowance account, provided it is no greater than the amount that would have been reported at the date of the reversal had the impairment not been recognized previously. The amount of the reversal is recognized in net income. The Company recognizes its transaction costs in net income in the period incurred. However, financial instruments that will not be subsequently measured at fair value are adjusted by the transaction costs that are directly attributable to their origination, issuance or assumption. FASB ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 establishes a three tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: ● Level 1. Observable inputs such as quoted prices in active markets; ● Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and ● Level 3. Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions. The Company measures its convertible debt and derivative liabilities associated therewith at fair value. These liabilities are revalued periodically and the resultant gain or loss is realized through the Statement of Operations and Comprehensive Loss. |
Related parties | l) Related parties Parties are considered to be related to the Company if the parties directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All transactions are recorded at fair value of the goods or services exchanged. |
Revenue Recognition | m) Revenue Recognition ASC 606 requires companies to exercise more judgment and recognize revenue using a five-step process. The Company’s provision for doubtful accounts are recorded as a direct reduction to revenue instead of being presented as a separate line item on the consolidated statements of operations and comprehensive loss. As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities. The Company receives payments from the following sources for services rendered in our U.S. Facility: (i) commercial insurers; and (ii) individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and does not adjust for the effects of a significant financing component. The Company derives a significant portion of its revenue from other payors that receive discounts from established billing rates. The various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management. Settlements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the Company’s financial condition or results of operations. The Company’s receivables were $ 291,011 176,011 The Company’s revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those services. The Company derives its revenues from the sale of its services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its revenue transactions: i. identify the contract with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to performance obligations in the contract; and v. recognize revenue as the performance obligation is satisfied. |
Income taxes | n) Income taxes The Company accounts for income taxes under the provisions of ASC Topic 740, ”Income Taxes”. ASC Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions taken or expected to be taken in a tax return. The first step is to determine if the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company recognizes interest and penalties accrued on unrecognized tax benefits within general and administrative expense. To the extent that accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction in general and administrative expenses in the period that such determination is made. |
Net income (loss) per Share | o) Net income (loss) per Share Basic net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the period. Diluted net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation. Dilution is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share). |
Stock based compensation | p) Stock based compensation Stock based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over the employee’s requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized in the consolidated statements of operations is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. |
Financial instruments Risks | q) Financial instruments Risks The Company is exposed to various risks through its financial instruments. The following analysis provides a measure of the Company’s risk exposure and concentrations at March 31, 2022 and December 31, 2021. i. Credit risk Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. Financial instruments that subject the Company to credit risk consist primarily of accounts receivable. Credit risk associated with accounts receivable is mitigated as only a percentage of the revenue billed to health insurance companies is recognized as income until such time as the actual funds are collected. The revenue is concentrated amongst several health insurance companies located in the US. In the opinion of management, credit risk with respect to accounts receivable is assessed as low. ii. Liquidity risk Liquidity risk is the risk the Company will not be able to meet its financial obligations as they fall due. The Company is exposed to liquidity risk through its working capital deficiency of $ 13,313,891 278,699 44,302,371 iii. Market risk Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises of three types of risk: interest rate risk, currency risk, and other price risk. The Company is exposed to interest rate risk and currency risk. a. Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its convertible debt, mortgage loans, short term loans, third party loans and government assistance loans as of March 31, 2022. In the opinion of management, interest rate risk is assessed as moderate. b. Currency risk Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company is subject to currency risk as it has subsidiaries that operate in Canada and are subject to fluctuations in the Canadian dollar. A substantial portion of the Company’s financial assets and liabilities are denominated in Canadian dollars. Based on the net exposures at March 31, 2022, a 5% depreciation or appreciation of the Canadian dollar against the U.S. dollar would result in an approximate $4,164 increase or decrease in the Company’s after tax net income from operations. The Company has not entered into any hedging agreements to mitigate this risk. In the opinion of management, currency risk is assessed as low, material and remains unchanged from that of the prior year. c. Other price risk Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. In the opinion of management, the Company is not exposed to this risk and remains unchanged from the prior year. |
Recent accounting pronouncements | r) Recent accounting pronouncements In August 2020, the Financial Accounting Standard board (“FASB”) issued ASU 2020-06 "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40) ("ASU 2020-06"). The update simplifies the accounting for convertible debt instruments and convertible preferred stock by reducing the number of accounting models and limiting the number of embedded conversion features separately recognized from the primary contract. The guidance also includes targeted improvements to the disclosures for convertible instruments and earnings per share. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company is assessing the impact, if any, on the adoption of this update on the Company's consolidated financial statements. The FASB issued several additional updates during the period, none of these standards are either applicable to the Company or require adoption at a future date and none are expected to have a material impact on the consolidated financial statements upon adoption. |
Comparative and prior period disclosures | t) Comparative and prior period disclosures The comparative and prior period disclosed amounts presented in these unaudited condensed consolidated financial statements have been reclassified where necessary to conform to the presentation used in the current period. |
Acquisition of subsidiaries (Ta
Acquisition of subsidiaries (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Acquisition Of Subsidiaries | |
Schedule of assets acquired and liabilities assumed | Schedule of assets acquired and liabilities assumed Amount Consideration Cash 50,000 100,000,000 shares of common stock at fair market value 410,000 Total purchase consideration $ 460,000 Recognized amounts of identifiable assets acquired and liabilities assumed Cash 60,324 Other Current assets 198,133 Property, plant and equipment 130,234 Right of use asset 1,772,560 Intangibles 1,789,903 Total assets 3,951,154 Less: liabilities assumed Current liabilities assumed (50,040 ) Intercompany advance (1,140,985 ) Operating lease liabilities assumed (1,836,151 ) Imputed Deferred taxation on identifiable intangible acquired (310,645 ) Total liabilities (3,337,821 ) Net identifiable assets acquired and liabilities assumed 613,333 Fair value of non-controlling interest (153,333 ) Total $ 460,000 |
Schedule of revenue and earnings | Schedule of revenue and earnings Revenue Earnings Actual from January 1, 2022 to March 31, 2022 $ 991,941 $ 84,070 2021 Supplemental pro forma from January 1, 2021 to March 31, 2021 $ 495,081 $ (2,651,152 ) |
Property and equipment (Tables)
Property and equipment (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Property, Plant and Equipment [Abstract] | |
Schedule of sale of property | Schedule of sale of property March 31, December 31, 2021 Cost Accumulated depreciation Net book value Net book value Land $ 172,055 $ — $ 172,055 $ 168,585 Property 3,254,757 (652,897 ) 2,601,860 2,596,590 Leasehold improvements 237,015 (17,718 ) 219,297 153,730 Furniture and fittings 53,556 (11,589 ) 41,967 42,140 Vehicles 55,949 (9,478 ) 46,471 49,268 Computer equipment 1,450 (222 ) 1,228 1,350 $ 3,774,782 $ (691,904 ) $ 3,082,878 $ 3,012,663 |
Intangibles (Tables)
Intangibles (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Intangible assets | Schedule of Intangible assets March 31, 2022 December 31, 2021 Cost Accumulated amortization Net book value Net book value Health care Provider license $ 1,789,903 $ (268,485 ) $ 1,521,418 $ 1,610,913 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Leases [Abstract] | |
Schedule of Right of use assets | Schedule of Right of use assets March 31, 2022 December 31, Non-current assets Right-of-use assets – finance leases, net of depreciation, included in Property and equipment $ 46,471 $ 49,268 Right-of-use assets - operating leases, net of amortization $ 1,590,752 $ 1,653,816 |
Schedule of Lease costs | Schedule of Lease costs Three months ended March 31, 2022 2021 Finance lease cost: Amortization of right-of-use assets $ 2,797 $ — Interest expense on finance lease liabilities 648 — Finance lease cost 3,445 — Operating lease cost $ 63,064 $ — Lease cost $ 63,064 $ — |
Schedule of Other lease | Schedule of Other lease Three months ended March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from finance leases $ (1,809 ) $ — Operating cash flows from operating leases (63,064 ) — $ (64,873 ) $ — Weighted average lease term – finance leases 4 years and seven months — Weighted average remaining lease term – operating leases 4 years and 10 months — Discount rate – finance leases 6.61 % — Discount rate – operating leases 4.64 % — |
Schedule of Finance lease liability | Schedule of Finance lease liability Amount Remainder of 2022 $ 7,372 2023 9,829 2024 9,829 2025 9,829 2026 7,902 Total undiscounted minimum future lease payments 44,761 Imputed interest (6,303 ) Total finance lease liability $ 38,458 Disclosed as: Current portion $ 7,507 Non-Current portion 30,951 Lease liability $ 38,458 |
Schedule of Operating lease liability | Schedule of Operating lease liability Amount Remainder of 2022 $ 250,047 2023 348,677 2024 366,110 2025 384,416 2026 437,407 Total undiscounted minimum future lease payments 1,786,657 Imputed interest (109,299 ) Total operating lease liability $ 1,677,358 Disclosed as: Current portion $ 254,340 Non-Current portion 1,425,018 Lease liability $ 1,677,358 |
Taxes Payable (Tables)
Taxes Payable (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Taxes Payable | |
Schedule of taxation payable | Schedule of taxation payable March 31, December 31, Payroll taxes $ 146,119 $ 144,020 HST/GST payable 137,200 123,134 Income tax payable 434,346 391,682 Taxes Payable $ 717,665 $ 658,836 |
Short-term Convertible Notes (T
Short-term Convertible Notes (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Debt Disclosure [Abstract] | |
Schedule of short-term convertible notes | Schedule of short-term convertible notes Interest rate Maturity Date Principal Interest Debt Discount March 31, 2022 December 31, 2021 Leonite Capital, LLC 12.0 % On Demand $ 129,379 $ 43,673 $ — $ 173,052 $ 315,579 Auctus Fund, LLC 0.0 % On Demand 80,000 — — 80,000 100,000 Labrys Fund, LP 12.0 % November 30, 2021 — 8,826 — 8,826 8,826 11.0 % May 7, 2022 389,045 — (75,420 ) 313,625 354,504 11.0 % June 2, 2022 230,000 20,074 (47,942 ) 202,132 148,488 Ed Blasiak 6.5 % September 14, 2021 55,000 5,591 — 60,591 59,697 Joshua Bauman 11.0 % October 21, 2022 150,000 7,278 (83,836 ) 73,442 32,387 Geneva Roth Remark Holdings, Inc. 8.0 % October 1, 2022 42,311 3,385 (21,329 ) 24,367 24,384 Series N convertible notes 6.0 % On Demand 3,229,000 666,845 — 3,895,845 3,848,073 $ 4,304,735 $ 755,672 $ (228,527 ) $ 4,831,880 $ 4,891,938 |
Mortgage loans (Tables)
Mortgage loans (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Mortgage Loans | |
Schedule of mortgage loans | Schedule of mortgage loans Interest Maturity Principal Accrued March 31, December 31, Cranberry Cove Holdings, Ltd. Pace Mortgage 4.2 % July 19, 2022 $ 3,884,941 $ 5,365 $ 3,890,306 $ 3,864,312 Disclosed as follows: Short-term portion $ 3,890,306 $ 3,864,312 |
Derivative liability (Tables)
Derivative liability (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Derivative Liability | |
Schedule of assumption used in Black Scholes | Schedule of assumption used in Black Scholes Three months ended Calculated stock price $ 0.0006 0.0010 Risk free interest rate 0.06 2.45 % Expected life of convertible notes and warrants 3 39 expected volatility of underlying stock 167.1 238.1 % Expected dividend rate 0 % |
Schedule of derivative liability | Schedule of derivative liability March 31, December 31, Opening balance $ 515,901 $ 4,765,387 Derivative liability extinguished on convertible notes converted to equity (39,726 ) (2,914,119 ) Derivative liability on issued convertible notes — 190,824 Fair value adjustments to derivative liability (197,476 ) (1,526,191 ) Closing balance $ 278,699 $ 515,901 |
Stockholder_s deficit (Tables)
Stockholder’s deficit (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Equity [Abstract] | |
Schedule of warrants outstanding | Schedule of warrants outstanding No. of shares Exercise price Weighted Outstanding as of January 1, 2021 615,561,379 $0.000675 to $0.12 $ 0.011380 Granted 471,010,103 $0.0020500 0.003080 Forfeited/cancelled (101,682,866 ) $0.0015 to $0.12 0.039029 Exercised (361,111,110 ) $0.00150 to $0.00205 0.003291 Outstanding as of December 31, 2021 623,777,506 $0.000675 to $0.12 $ 0.0052875 Granted — — — Forfeited/cancelled (12,637,500 ) $0.12 0.12 Exercised — — — Outstanding as of March 31, 2022 611,140,006 $0.000675 to $0.12 $ 0.0029154 |
Schedule of assumption | Schedule of assumption Warrants outstanding Warrants exercisable Exercise price No. of shares Weighted average remaining years Weighted average exercise price No. of shares Weighted average exercise price $0.000675 326,286,847 3.28 326,286,847 $0.002050 276,565,659 3.77 276,565,659 $0.120000 8,287,500 0.27 8,287,500 611,140,006 3.46 $ 0.0029154 611,140,006 $ 0.0029154 |
Segment information (Tables)
Segment information (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Segment Information | |
Schedule of segment information | Schedule of segment information Three months ended March 31, 2022 Rental In-Patient Total Revenue $ 93,874 $ 929,441 $ 1,023,315 Operating expenses (33,316 ) (915,059 ) (948,375 ) Operating income 60,558 14,382 74,940 Other (expense) income Other income — 10,018 10,018 Interest expense (53,607 ) (27,161 ) (80,768 ) Amortization of debt discount — (252,832 ) (252,832 ) Derivative liability movement — 197,476 197,476 Foreign exchange movements (21,829 ) (73,727 ) (95,556 ) Net loss before taxes (14,878 ) (131,844 ) (146,722 ) Taxes — (18,263 ) (18,263 ) Net loss $ (14,878 ) $ (150,107 ) $ (164,985 ) The operating assets and liabilities of the reportable segments as of March 31, 2022 is as follows: March 31, 2022 Rental In-Patient Total Purchase of fixed assets $ — $ 72,858 $ 72,858 Assets Current assets 551 355,167 355,718 Non-current assets 2,773,914 3,426,324 6,200,238 Liabilities Current liabilities (1,590,715 ) (12,078,894 ) (13,669,609 ) Non-current liabilities (636,577 ) (1,710,232 ) (2,346,809 ) Mandatory redeemable preferred shares — (400,000 ) (400,000 ) Intercompany balances 1,238,399 (1,238,399 ) — Net liability position $ 1,785,572 $ (11,646,034 ) $ (9,860,462 ) Three months ended March 31, 2021 Rental Operations In-Patient services Total Revenue $ 90,793 $ — $ 90,793 Operating expenditure (32,849 ) (19,167 ) (52,016 ) Operating income (loss) 57,944 (19,167 ) 38,777 Other (expense) income Penalty on convertible notes — (9,240 ) (9,240 ) Fair value of warrants granted — (976,788 ) (976,788 ) Fair value of warrants exercised — (90,000 ) (90,000 ) Interest expense (59,745 ) (77,932 ) (137,677 ) Amortization of debt discount — (502,677 ) (502,677 ) Derivative liability movement — (611,059 ) (611,059 ) Foreign exchange movements (18,695 ) (60,797 ) (79,492 ) Net loss before taxation (20,496 ) (2,347,660 ) (2,368,156 ) Taxation — — — Net loss $ (20,496 ) $ (2,347,660 ) $ (2,368,156 ) The operating assets and liabilities of the reportable segments as of March 31, 2021 is as follows: March 31, 2021 Rental Operations In-Patient services Total Purchase of fixed assets $ — $ — $ — Assets Current assets 4,580 1,196,939 1,201,519 Non-current assets 2,885,861 5,157 2,891,018 Liabilities Current liabilities (1,484,968 ) (12,388,857 ) (13,873,825 ) Non-current liabilities (4,645,209 ) — (4,645,209 ) Mandatory redeemable preferred shares — (400,000 ) (400,000 ) Intercompany balances 1,330,423 (1,330,423 ) — Net liability position $ (1,909,313 ) $ (12,917,184 ) $ (14,826,497 ) |
Net (loss) income per common _2
Net (loss) income per common share (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of Antidilutive Securities | Schedule of Antidilutive Securities Three months ended Three months ended Warrants to purchase shares of common stock 611,140,006 926,470,474 Convertible notes 458,435,448 662,500,729 1,069,575,454 1,588,971,203 |
Summary of significant accoun_3
Summary of significant accounting policies (Details Narrative) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2021 | |
Accounting Policies [Abstract] | ||
Receivables | $ 291,011 | $ 176,011 |
Working capital deficiency | 13,313,891 | |
Derivative Liability, Current | 278,699 | 515,901 |
Retained Earnings (Accumulated Deficit) | $ 44,302,371 | $ 44,103,311 |
Acquisition of subsidiaries (De
Acquisition of subsidiaries (Details) | Mar. 31, 2022USD ($) |
Consideration | |
Cash | $ 50,000 |
100,000,000 shares of common stock at fair market value | 410,000 |
Total purchase consideration | 460,000 |
Recognized amounts of identifiable assets acquired and liabilities assumed | |
Cash | 60,324 |
Other Current assets | 198,133 |
Property, plant and equipment | 130,234 |
Right of use asset | 1,772,560 |
Intangibles | 1,789,903 |
Total assets | 3,951,154 |
Less: liabilities assumed | |
Current liabilities assumed | (50,040) |
Intercompany advance | (1,140,985) |
Operating lease liabilities assumed | (1,836,151) |
Imputed Deferred taxation on identifiable intangible acquired | (310,645) |
Total liabilities | (3,337,821) |
Net identifiable assets acquired and liabilities assumed | 613,333 |
Fair value of non-controlling interest | (153,333) |
Total | $ 460,000 |
Acquisition of subsidiaries (_2
Acquisition of subsidiaries (Details 1) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Acquisition Of Subsidiaries | ||
Pro forma revenue | $ 991,941 | $ 495,081 |
Pro forma earnings | $ 84,070 | $ (2,651,152) |
Property and equipment (Details
Property and equipment (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Property, Plant and Equipment [Line Items] | ||
Cost | $ 3,774,782 | |
Accumulated Depreciation | (691,904) | |
Net book value | 3,082,878 | $ 3,012,663 |
Land [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 172,055 | |
Accumulated Depreciation | ||
Net book value | 172,055 | 168,585 |
Property, Plant and Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 3,254,757 | |
Accumulated Depreciation | (652,897) | |
Net book value | 2,601,860 | 2,596,590 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 237,015 | |
Accumulated Depreciation | (17,718) | |
Net book value | 219,297 | 153,730 |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 53,556 | |
Accumulated Depreciation | (11,589) | |
Net book value | 41,967 | 42,140 |
Vehicles [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 55,949 | |
Accumulated Depreciation | (9,478) | |
Net book value | 46,471 | 49,268 |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 1,450 | |
Accumulated Depreciation | (222) | |
Net book value | $ 1,228 | $ 1,350 |
Property and equipment (Detai_2
Property and equipment (Details Narrative) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation | $ 132,000 | $ 32,125 |
Intangibles (Details)
Intangibles (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Cost | $ 1,789,903 | |
Accumulated amortization | (268,485) | |
Net book value | $ 1,521,418 | $ 1,610,913 |
Intangibles (Details Narrative)
Intangibles (Details Narrative) | 3 Months Ended |
Mar. 31, 2022USD ($) | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Amortization expense for finite-lived assets | $ 89,495 |
Leases (Details)
Leases (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Non-current assets | ||
Right-of-use assets – finance leases, net of depreciation, included in Property and equipment | $ 46,471 | $ 49,268 |
Right-of-use assets - operating leases, net of amortization | $ 1,590,752 | $ 1,653,816 |
Leases (Details 1)
Leases (Details 1) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Finance lease cost: | ||
Amortization of right-of-use assets | $ 2,797 | |
Interest expense on finance lease liabilities | 648 | |
Finance lease cost | 3,445 | |
Operating lease cost | 63,064 | |
Lease cost | $ 63,064 |
Leases (Details 2)
Leases (Details 2) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Leases [Abstract] | ||
Operating cash flows from finance leases | $ (1,809) | |
Operating cash flows from operating leases | (63,064) | |
Financing cash flows from finance leases | $ (64,873) | |
Weighted average lease term - finance leases | 4 years and seven months | |
Weighted average remaining lease term- operating leases (in years) | 4 years and 10 months | |
Lessee, Finance Lease, Discount Rate | 6.61% | |
Operating Lease, Weighted Average Discount Rate, Percent | 4.64% |
Leases (Details 3)
Leases (Details 3) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Leases [Abstract] | ||
Remainder of 2022 | $ 7,372 | |
2023 | 9,829 | |
2024 | 9,829 | |
2025 | 9,829 | |
2026 | 7,902 | |
Total undiscounted minimum future lease payments | 44,761 | |
Imputed interest | (6,303) | |
Total finance lease liability | 38,458 | |
Current portion | 7,507 | $ 7,386 |
Non-Current portion | $ 30,951 | $ 32,895 |
Leases (Details 4)
Leases (Details 4) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Leases [Abstract] | ||
Remainder of 2022 | $ 250,047 | |
2023 | 348,677 | |
2024 | 366,110 | |
2025 | 384,416 | |
2026 | 437,407 | |
Total undiscounted minimum future lease payments | 1,786,657 | |
Imputed interest | (109,299) | |
Lease liability | 1,677,358 | |
Current portion | 254,340 | |
Non-Current portion | $ 1,425,018 | $ 1,493,431 |
Taxes Payable (Details)
Taxes Payable (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Taxes Payable | ||
Payroll taxes | $ 146,119 | $ 144,020 |
HST/GST payable | 137,200 | 123,134 |
Income tax payable | 434,346 | 391,682 |
Taxes Payable | $ 717,665 | $ 658,836 |
Short-term Convertible Notes (D
Short-term Convertible Notes (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2021 | |
Short-Term Debt [Line Items] | ||
Principal | $ 4,304,735 | |
Interest | 755,672 | |
Debt Discount | (228,527) | |
Total | $ 4,831,880 | $ 4,891,938 |
Leonite Capital LLC [Member] | ||
Short-Term Debt [Line Items] | ||
Short-term Debt, Interest Rate Increase | 12.00% | |
Principal | $ 129,379 | |
Interest | 43,673 | |
Debt Discount | ||
Total | $ 173,052 | 315,579 |
Auctus Fund, LLC [Member] | ||
Short-Term Debt [Line Items] | ||
Short-term Debt, Interest Rate Increase | 0.00% | |
Principal | $ 80,000 | |
Interest | ||
Debt Discount | ||
Total | $ 80,000 | 100,000 |
Maturity date | On Demand | |
Labrys Fund, LP [Member] | ||
Short-Term Debt [Line Items] | ||
Short-term Debt, Interest Rate Increase | 12.00% | |
Principal | ||
Interest | 8,826 | |
Debt Discount | ||
Total | $ 8,826 | 8,826 |
Maturity date | November 30, 2021 | |
Labrys Fund, LP 2[Member] | ||
Short-Term Debt [Line Items] | ||
Short-term Debt, Interest Rate Increase | 11.00% | |
Principal | $ 389,045 | |
Interest | ||
Debt Discount | (75,420) | |
Total | $ 313,625 | 354,504 |
Maturity date | May 7, 2022 | |
Labrys Fundlp 3 [Member] | ||
Short-Term Debt [Line Items] | ||
Short-term Debt, Interest Rate Increase | 11.00% | |
Principal | $ 230,000 | |
Interest | 20,074 | |
Debt Discount | (47,942) | |
Total | $ 202,132 | 148,488 |
Maturity date | June 2, 2022 | |
Ed Blasiak | ||
Short-Term Debt [Line Items] | ||
Short-term Debt, Interest Rate Increase | 6.50% | |
Principal | $ 55,000 | |
Interest | 5,591 | |
Debt Discount | ||
Total | $ 60,591 | 59,697 |
Maturity date | September 14, 2021 | |
Joshua Bauman | ||
Short-Term Debt [Line Items] | ||
Short-term Debt, Interest Rate Increase | 11.00% | |
Principal | $ 150,000 | |
Interest | 7,278 | |
Debt Discount | (83,836) | |
Total | $ 73,442 | 32,387 |
Maturity date | October 21, 2022 | |
Geneva Roth Remark Holdings Inc | ||
Short-Term Debt [Line Items] | ||
Short-term Debt, Interest Rate Increase | 8.00% | |
Principal | $ 42,311 | |
Interest | 3,385 | |
Debt Discount | (21,329) | |
Total | $ 24,367 | 24,384 |
Maturity date | October 1, 2022 | |
Series N Convertible Notes [Member] | ||
Short-Term Debt [Line Items] | ||
Short-term Debt, Interest Rate Increase | 6.00% | |
Principal | $ 3,229,000 | |
Interest | 666,845 | |
Debt Discount | ||
Total | $ 3,895,845 | $ 3,848,073 |
Maturity date | On Demand |
Mortgage loans (Details)
Mortgage loans (Details) - Pace Mortgage [Member] - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2021 | |
Short-Term Debt [Line Items] | ||
Debt Instrument, Interest Rate, Stated Percentage | 4.20% | |
Debt Instrument, Maturity Date | Jul. 19, 2022 | |
Principal Outstanding | $ 3,884,941 | |
Debt Instrument, Increase, Accrued Interest | 5,365 | |
Loans Payable | 3,890,306 | $ 3,864,312 |
Loans Payable, Current | $ 3,890,306 | $ 3,864,312 |
Derivative liability (Details)
Derivative liability (Details) | 3 Months Ended |
Mar. 31, 2022$ / shares | |
Calculated stock price, min | $ 0.0006 |
Calculated stock price, max | $ 0.0010 |
Expected life of convertible notes and warrants, minimum | 3 months |
Expected life of convertible notes and warrants, maximum | 39 months |
Expected dividend rate | 0.00% |
Minimum [Member] | |
Risk free interest rate | 0.06% |
Expected volatility of underlying stock | 167.10% |
Maximum [Member] | |
Risk free interest rate | 2.45% |
Expected volatility of underlying stock | 238.10% |
Derivative liability (Details 1
Derivative liability (Details 1) - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
Derivative Liability | ||
Opening Balance | $ 515,901 | $ 4,765,387 |
Mark-to-market adjustments on converted notes | (39,726) | (2,914,119) |
Derivative liability arising from convertible notes | 190,824 | |
Fair value adjustment to derivative liability | (197,476) | (1,526,191) |
Closing Balance | $ 278,699 | $ 515,901 |
Derivative liability (Details N
Derivative liability (Details Narrative) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Derivative Liability | ||
Derivative Liability, Current | $ 278,699 | $ 515,901 |
Related party transactions (Det
Related party transactions (Details Narrative) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Shawn Leon [Member] | ||
Related Party Transaction [Line Items] | ||
Accounts Payable, Related Parties, Current | $ 341,379 | $ 106,100 |
Leon Developments Ltd [Member] | ||
Related Party Transaction [Line Items] | ||
Accounts Payable, Related Parties, Current | 955,398 | 935,966 |
Eileen Greene [Member] | ||
Related Party Transaction [Line Items] | ||
Accounts Payable, Related Parties, Current | $ 1,496,164 | $ 1,472,215 |
Stockholders' deficit - (Detail
Stockholders' deficit - (Details) - Warrants - $ / shares | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
Class of Warrant or Right [Line Items] | ||
Beginning balance, warrants | 623,777,506 | 615,561,379 |
Exercise price, Beginning balance | $0.000675 to $0.12 | $0.000675 to $0.12 |
Weighted average exercise price Beginning balance | $ 0.0052875 | $ 0.011380 |
Warrants Granted, shares | 471,010,103 | |
Exercise price, Granted | $0.0020500 | |
Weighted average exercise price Granted | $ 0.003080 | |
Warrants Forfeited/cancelled, shares | (12,637,500) | (101,682,866) |
Exercise price forfeited/cancelled | $0.12 | $0.0015 to $0.12 |
Weighted average exercise price Forfeited/cancelled | $ 0.12 | $ 0.039029 |
Warrant Exercised, shares | (361,111,110) | |
Exercise Price Exercised | $0.00150 to $0.00205 | |
Weighted average exercise price Exercised | $ 0.003291 | |
Warrant Exercised, shares | 361,111,110 | |
Ending Balance, warrants | 611,140,006 | 623,777,506 |
Exercise price ending balance | $0.000675 to $0.12 | |
Weighted average exercise price Ending balance | $ 0.0029154 | $ 0.0052875 |
Stockholders' deficit - (Deta_2
Stockholders' deficit - (Details 1) | Mar. 31, 2022$ / sharesshares |
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Warrants outstanding | 611,140,006 |
Warrants and Rights Outstanding, Term | 3 years 5 months 15 days |
Warrants exercisable | 611,140,006 |
Weighted average exercise price, Warrants outstanding | $ / shares | $ 0.0029154 |
Weighted average exercise price, Warrants exercisable | $ / shares | $ 0.0029154 |
Excercise 1 [Member] | |
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Warrants outstanding | 326,286,847 |
Warrants and Rights Outstanding, Term | 3 years 3 months 10 days |
Warrants exercisable | 326,286,847 |
Excercise 2 [Member] | |
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Warrants outstanding | 276,565,659 |
Warrants and Rights Outstanding, Term | 3 years 9 months 7 days |
Warrants exercisable | 276,565,659 |
Excercise 3 [Member] | |
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Warrants outstanding | 8,287,500 |
Warrants and Rights Outstanding, Term | 3 months 7 days |
Warrants exercisable | 8,287,500 |
Segment information (Details)
Segment information (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | |
Revenue | $ 1,023,315 | $ 90,793 | |
Operating income (loss) | 74,940 | 38,777 | |
Other (expense) income | |||
Interest expense | (80,768) | (137,677) | |
Amortization of debt discount | 252,832 | 502,677 | |
Foreign exchange movements | (95,556) | (79,492) | |
Assets | |||
Current assets | 355,718 | $ 271,799 | |
Non-current assets | 6,200,238 | 6,282,507 | |
Liabilities | |||
Current liabilities | (13,669,609) | $ (13,516,802) | |
Rental Operations [Member] | |||
Revenue | 93,874 | 90,793 | |
Operating expenditure | (33,316) | (32,849) | |
Operating income (loss) | 60,558 | 57,944 | |
Other (expense) income | |||
Other income | |||
Interest expense | 53,607 | (59,745) | |
Amortization of debt discount | |||
Derivative liability movement | |||
Derivative liability movement | |||
Foreign exchange movements | 21,829 | (18,695) | |
Net loss before taxation | (14,878) | (20,496) | |
Taxation | |||
Net loss | (14,878) | (20,496) | |
Purchase of fixed assets | |||
Assets | |||
Current assets | 551 | 4,580 | |
Non-current assets | 2,773,914 | 2,885,861 | |
Liabilities | |||
Current liabilities | 1,590,715 | (1,484,968) | |
Non-current liabilities | (636,577) | (4,645,209) | |
Mandatory redeemable preferred shares | |||
Intercompany balances | 1,238,399 | 1,330,423 | |
Net liability position | 1,785,572 | (1,909,313) | |
Penalty on convertible notes | |||
Fair value of warrants granted | |||
Fair value of warrants exercised | |||
In Patient Services [Member] | |||
Revenue | 929,441 | ||
Operating expenditure | (915,059) | (19,167) | |
Operating income (loss) | 14,382 | (19,167) | |
Other (expense) income | |||
Other income | 10,018 | ||
Interest expense | 27,161 | (77,932) | |
Amortization of debt discount | (252,832) | (502,677) | |
Derivative liability movement | (611,059) | ||
Derivative liability movement | 197,476 | ||
Foreign exchange movements | 73,727 | (60,797) | |
Net loss before taxation | (131,844) | (2,347,660) | |
Taxation | (18,263) | ||
Net loss | (150,107) | (2,347,660) | |
Purchase of fixed assets | 72,858 | ||
Assets | |||
Current assets | 355,167 | 1,196,939 | |
Non-current assets | 3,426,324 | 5,157 | |
Liabilities | |||
Current liabilities | 12,078,894 | (12,388,857) | |
Non-current liabilities | (1,710,232) | ||
Mandatory redeemable preferred shares | (400,000) | (400,000) | |
Intercompany balances | (1,238,399) | (1,330,423) | |
Net liability position | (11,646,034) | (12,917,184) | |
Penalty on convertible notes | (9,240) | ||
Fair value of warrants granted | (976,788) | ||
Fair value of warrants exercised | (90,000) | ||
Total [Member] | |||
Revenue | 1,023,315 | 90,793 | |
Operating expenditure | (948,375) | (52,016) | |
Operating income (loss) | 74,940 | 38,777 | |
Other (expense) income | |||
Other income | 10,018 | ||
Interest expense | 80,768 | (137,677) | |
Amortization of debt discount | (252,832) | (502,677) | |
Derivative liability movement | (611,059) | ||
Derivative liability movement | 197,476 | ||
Foreign exchange movements | 95,556 | (79,492) | |
Net loss before taxation | (146,722) | (2,368,156) | |
Taxation | (18,263) | ||
Net loss | (164,985) | (2,368,156) | |
Purchase of fixed assets | 72,858 | ||
Assets | |||
Current assets | 355,718 | 1,201,519 | |
Non-current assets | 6,200,238 | 2,891,018 | |
Liabilities | |||
Current liabilities | 13,669,609 | (13,873,825) | |
Non-current liabilities | (2,346,809) | (4,645,209) | |
Mandatory redeemable preferred shares | (400,000) | (400,000) | |
Intercompany balances | |||
Net liability position | $ (9,860,462) | (14,826,497) | |
Penalty on convertible notes | (9,240) | ||
Fair value of warrants granted | (976,788) | ||
Fair value of warrants exercised | $ (90,000) |
Net (loss) income per common _3
Net (loss) income per common share (Details) - shares | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive shares | 1,069,575,454 | 1,588,971,203 |
Warrants | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive shares | 611,140,006 | 926,470,474 |
Convertible Notes [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive shares | 458,435,448 | 662,500,729 |